Figure 4
Figure 4. Serum antibody to SLAdd cells after single administration of cells. Control animals injected with 1 × 108 PBMCs (A) demonstrated production of IgG antibody to SLAdd PBMCs within 2 weeks of injection. Animals receiving one injection of 108 unactivated UTCs either intravenously or subcutaneously (B) did not have detectable antibody. IgG antibody production was also seen in animals injected with 108 activated UTCs (aUTCs) expressing MHCII (C) and in animals receiving 108 UTCs injected around an inflammatory lesion (CFA/UTC) (D), as well as after in animals receiving repeated doses (108 cells/dose) of UTCs (E).

Serum antibody to SLAdd cells after single administration of cells. Control animals injected with 1 × 108 PBMCs (A) demonstrated production of IgG antibody to SLAdd PBMCs within 2 weeks of injection. Animals receiving one injection of 108 unactivated UTCs either intravenously or subcutaneously (B) did not have detectable antibody. IgG antibody production was also seen in animals injected with 108 activated UTCs (aUTCs) expressing MHCII (C) and in animals receiving 108 UTCs injected around an inflammatory lesion (CFA/UTC) (D), as well as after in animals receiving repeated doses (108 cells/dose) of UTCs (E).

Close Modal

or Create an Account

Close Modal
Close Modal